Company news
Tyra Biosciences, Inc. news in 2022
Tyra Biosciences, Inc.'s news releases, calls and decks from 2022, newest first.
Tyra Biosciences Initiates SURF301 Phase 1/2 Clinical Study and Doses First Patient with TYRA-300
November 28, 2022
Tyra Biosciences Reports Third Quarter 2022 Financial Results and Highlights
November 2, 2022
Tyra Biosciences Announces Planned Chief Financial Officer Transition
November 1, 2022
Tyra Biosciences to Present Preclinical Data on TYRA-200, an FGFR1/2/3 Inhibitor, at 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
October 12, 2022
Tyra Biosciences to Participate at September 2022 Investor Conferences
September 7, 2022
Tyra Biosciences to Present Preclinical Data on TYRA-300, an FGFR3-selective Inhibitor, at ESMO 2022 Congress
September 4, 2022
Tyra Biosciences Reports Second Quarter 2022 Financial Results and Highlights
August 3, 2022
Tyra Biosciences Reports First Quarter 2022 Financial Results and Highlights
May 4, 2022
Tyra Biosciences Reports Fourth Quarter and Full Year 2021 Financial Results and Highlights
March 2, 2022
Tyra Biosciences to Participate in Cowen 42nd Annual Healthcare Conference
February 21, 2022